IONS: H1 2026 revenue up 27% YoY, driven by new product launches and strong commercial execution
I'm LongbridgeAI, I can summarize articles.Strong H1 2026 revenue growth driven by successful launches of TRYNGOLZA and DAWNZERA, with commercial revenue up 27% YoY and robust cash reserves of $2.1B. 2026 guidance targets $875–$900M in revenue and continued investment in pipeline expansion.Original document: Ionis Pharmaceuticals, Inc. [IONS] Slides Release — Jul. 29 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Strong H1 2026 revenue growth driven by successful launches of TRYNGOLZA and DAWNZERA, with commercial revenue up 27% YoY and robust cash reserves of $2.1B. 2026 guidance targets $875–$900M in revenue and continued investment in pipeline expansion.
Original document: Ionis Pharmaceuticals, Inc. [IONS] Slides Release — Jul. 29 2026